Medicus Pharma Ltd. (NASDAQ:MDCX – Free Report) – Analysts at Brookline Capital Management issued their Q1 2025 earnings per share (EPS) estimates for shares of Medicus Pharma in a research report issued on Tuesday, April 8th. Brookline Capital Management analyst K. Raja forecasts that the company will post earnings of ($0.23) per share for the quarter. Brookline Capital Management has a “Strong-Buy” rating on the stock. The consensus estimate for Medicus Pharma’s current full-year earnings is ($1.14) per share. Brookline Capital Management also issued estimates for Medicus Pharma’s Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.23) EPS and FY2029 earnings at $1.68 EPS.
Separately, Maxim Group assumed coverage on shares of Medicus Pharma in a research report on Tuesday, December 17th. They set a “buy” rating and a $10.00 target price for the company.
Medicus Pharma Trading Down 11.1 %
MDCX stock opened at $3.35 on Thursday. Medicus Pharma has a 12 month low of $1.80 and a 12 month high of $6.00. The company has a fifty day simple moving average of $3.42.
Medicus Pharma (NASDAQ:MDCX – Get Free Report) last issued its earnings results on Friday, March 28th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.14.
Institutional Trading of Medicus Pharma
An institutional investor recently bought a new position in Medicus Pharma stock. Interchange Capital Partners LLC acquired a new position in shares of Medicus Pharma Ltd. (NASDAQ:MDCX – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 1,457,165 shares of the company’s stock, valued at approximately $3,628,000. Medicus Pharma accounts for approximately 1.3% of Interchange Capital Partners LLC’s investment portfolio, making the stock its 15th biggest position. Interchange Capital Partners LLC owned 13.43% of Medicus Pharma as of its most recent SEC filing.
Medicus Pharma Company Profile
Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.
Read More
- Five stocks we like better than Medicus Pharma
- Stock Splits, Do They Really Impact Investors?
- Joby Aviation: Operational Momentum vs. Market Sentiment
- Earnings Per Share Calculator: How to Calculate EPS
- Broadcom’s Big Outperformance Shows Strength Amid Tariff Decline
- Why Invest in High-Yield Dividend Stocks?
- Carvana: Can Turnaround Strength Outdrive Market Headwinds?
Receive News & Ratings for Medicus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
